Status:
UNKNOWN
Pharmacokinetics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Patients During Laparoscopic Surgery
Lead Sponsor:
Guangzhou General Hospital of Guangzhou Military Command
Conditions:
Pharmacokinetics
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to illustrate pharmacokinetics of sugammadex in reversal of vecuronium-induced neuromuscular blockade in patients during laparoscopic surgery
Detailed Description
48 patients undergoing laparoscopic surgery were divided into 3 groups according to body mass index (BMI), including normal weight group(A group,n=16,18.5kg/m² ≤ BMI ≤ 24.9kg/m²),obese group (B group,...
Eligibility Criteria
Inclusion
- ASA: Ⅰ\~Ⅲ
- BMI≥25kg/m²
- Patients receiving bariatric surgery.
Exclusion
- Pregnant or lactating women
- Neuromuscular diseases
- Malignant hyperthermia or allergic history during general anesthesia
- Drugs that react with rocuronium and vecuronium were taken
Key Trial Info
Start Date :
July 16 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2022
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT05328778
Start Date
July 16 2019
End Date
November 30 2022
Last Update
April 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou Military Region General Hospital, Department of Anesthesiology
Guangzhou, Guangdong, China, 510010